Systemic Ketone Replacement Does Not Improve Survival or Cancer Cachexia in Mice With Lung Cancer.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study
PubMed 35719965 · doi:10.3389/fonc.2022.903157
What was done
Male and female mice with induced lung cancer were evaluated across two dietary intervention studies to test whether restoring circulating ketone levels reduces cancer cachexia. In the first study, mice were randomized to consume either a very low carbohydrate ketogenic diet (KD) or normal chow (NC) following tumor induction. In the second study, tumor-bearing mice were randomized to receive a diet compounded with a ketone ester supplement (KE) or standard NC. Investigators assessed circulating ketone bodies, blood glucose, body weight maintenance, survival, and hepatic mRNA expression of PPARα target genes.
What was found
The abstract provides no numerical data. KD elevated serum ketone levels and reduced blood glucose but did not improve body weight maintenance or survival, showing a trend toward worsened survival in male mice. KE supplementation acutely and chronically increased serum ketone bodies and upregulated hepatic PPARα target gene expression, but similarly failed to improve weight maintenance or survival in male or female mice.
Why it matters
This study shows that circulating ketone deficiency is likely a downstream feature rather than a direct therapeutic target in lung cancer cachexia, indicating that dietary ketone restoration alone does not rescue weight loss or extend survival.
Limits
The findings are limited to an animal model and cannot be directly applied to human clinical cachexia. The abstract omits sample sizes, specific cancer cell lines, dosage details, and exact numerical measurements for survival and tissue wasting.
Cited by
- contradicts Ketone ester supplementation elevating both beta-hydroxybutyrate and acetoacetate prevents muscle wasting in experimental models of cachexia.